Vijaya Diagnostic Centre Limited

Healthcare — Diagnostics & Research · NSE

₹1,370.50−₹16.90 (−1.22%)

DalalBaazaar Score

74 / 100

🟢 Good

Verdict

REASONABLE

Risk

Moderate

Driven by small-cap size, which brings sharper price swings, a very high earnings multiple, which leaves little margin for disappointment.

In simple words: Strong business and financial position, with both sales and profits growing well. Valuation is currently the main factor to watch.

Decision support, not a buy or sell call.

As of 18 Oct 2026, 7:03 pm

Understanding the Business

Company site ↗

The 60-second version of Vijaya Diagnostic Centre Limited — what it does, how it earns, and who it competes with, before any of the numbers below.

What does this company do?

Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India.

IndustryDiagnostics & Research

SectorHealthcare

Employees2,507

Annual revenue₹814 Cr

How does it make money?

Turns over ₹814 Cr a year. Of every ₹100 of sales, about ₹21 reaches shareholders as profit, with ₹42 left at the operating level before interest, tax and depreciation. Each of its 2,507 employees supports ₹32.5 lakh of revenue a year, the signature of a people-led business.

Revenue / employee₹32.5 lakh

Who are its competitors?

The closest listed comparisons in its industry are SUN PHARMACEUTICAL IND L, CIPLA LTD, DR. REDDY S LABORATORIES, APOLLO HOSPITALS ENTER. L. These are the companies its valuation and returns are measured against elsewhere in this report.

Compared side by side in Peers ↓

What is its competitive advantage?Some evidence

ROCE of 19.1% is above what capital typically costs, which suggests some pricing power, though not yet the sustained, wide gap that marks a durable advantage.

Peer median ROE14.5%

What is the outlook?

10 analysts covering the stock expect revenue to grow about 20.4% and earnings to grow about 26.7% in the year to 2028. These are estimates by people who follow the company, not a forecast for the wider industry.

Est. revenue growth+20.4%

Est. earnings growth+26.7%

Analysts10

What has been driving growth?

Growth has come mainly from selling more, rather than from keeping more of each sale. Over 3 years revenue moved +77% while net margin moved +15% relative to itself. What this cannot tell you is which products, customers or geographies did the work — that lives in the segment disclosures of the annual report.

Revenue effect+77%

Margin effect+15%

DalalBaazaar Score

74/ 100

Good

Weighted across six categories. Every point is explained below.

✗ P/E of 75.3x is demanding — it needs sustained high growth to justify
• P/E is close to its own historical median of 82.3x
✗ P/B of 14.73x is a steep premium to book

Quality vs. Valuation

Company Quality

84/ 100

Excellent

How good the business is, ignoring the share price entirely.

Valuation

32/ 100

Expensive

What you are being asked to pay, ignoring how good the business is.

A good business, but the price already reflects that. The quality is real; the question is whether you are overpaying for it today.

Historical Valuation

Current P/E

75.3x

3Y Median

82.3x

40 monthly readings · mean 81.8x · range 60.4x–100.7x

Sector Median

33.3x

median of 4 sector peers

🟡Currently trading close to its 3y median of 82.3x — the market is paying about what it usually pays for this company.

⚠️Against its sector it trades 126% above the peer median of 33.3x.

vs. its own history

Fair

82.3x median over 40 months · -8%

vs. sector peers

Expensive

33.3x median of 4 peers · +126%

vs. generic bands

Expensive

Above 35x

EV/EBITDA

42.5x

PEG

2.80

What's Good / What's Bad

🟢 What's Going Well3

Cash generation is improving
Free cash flow is up 121% over 3 years.
Return on capital is rising
ROCE has improved from 16.9% to 19.1%.
Consistently profitable
Profitable in every one of the last 4 reported years.

🔴 What Needs Attention0

Nothing stands out as clearly deteriorating on the years of data available.

Red Flags

3 items require attention · 2 high · 1 watch

🔴Debt has risen sharplyFinancial
Total debt is up 71% over 3 years, from ₹248 Cr to ₹423 Cr.
🔴Inventory building faster than salesFinancial
Inventory up 139% against revenue up 77% — stock may not be moving.
🟡Receivables growing faster than salesFinancial
Receivables up 120% against revenue up 77% — sales are being booked faster than they are collected.

Investment Thesis

🟢 Bull CaseWhat could make this work?

Capital compounds at a high rate
ROCE of 19.1% means each rupee reinvested earns well above what capital costs. If the company can keep deploying at this rate, growth creates value rather than just consuming cash.
Self-funding with balance-sheet headroom
Positive free cash flow of ₹88 Cr alongside low debt means growth, buybacks or dividends need no outside money — and a downturn can be absorbed rather than refinanced.
Earnings have proved durable
Profitable in every one of the last 4 reported years. Consistency lowers the risk that any single bad year is structural rather than cyclical.

🔴 Bear CaseWhat could go wrong?

Sales are being booked faster than collected
Receivables are up 120% against revenue up 77%. If customers keep taking longer to pay, reported profit will not turn into cash — and write-offs follow if some never do.
A premium to the sector to defend
It trades 126% above the peer median. That premium needs a reason that persists, or it closes.
Size brings its own risk
Small Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.
Several serious flags at once
2 high-severity checks triggered. Individually each has an explanation; together they raise the chance that something structural is wrong rather than a one-off.

🟡 Key Things to WatchMeasurable tripwires, set against where this company stands today

1Revenue growth stays above 16% a year✓ 21.0% CAGR
Latest reported year was 22.8%. The bar is set below the established compounding rate, so ordinary variation does not trip it.
2EBITDA margin holds above 40%✓ 41.9%
Two points below today's level — enough room for noise, tight enough to catch real compression.
3Free cash flow remains positive✓ ₹88 Cr
Profit that never becomes cash eventually stops being profit.
4Debt / EBITDA stays below 2x✓ 1.2x
The ratio lenders write covenants against; it survives a small or negative equity base, unlike Debt/Equity.
5ROCE stays above 16%✓ 19.1%
Falling returns on capital are usually competition arriving, and show up here before they reach the margin.

Investment Checklist

10 / 12 checks passed

✓ Strong return on equity (ROE ≥ 15%)
✓ Strong return on capital employed (ROCE ≥ 15%)
✓ Healthy net margin (≥ 10%)
✓ Generates positive free cash flow
✓ Manageable leverage (Debt/Equity < 1.0)
✓ Adequate short-term liquidity (Current Ratio ≥ 1.0)
✓ Revenue growing year-over-year
✓ Profit growing year-over-year
✗ Not trading at an extreme valuation (P/E < 40x)
✓ Not buying right at the 52-week high
✓ Analyst consensus isn't majority-sell
✗ Short-term technical trend isn't bearish

Price history

Quick Metrics

7 good · 2 neutral · 2 weak

Market Cap

₹14,116 Cr

Small Cap

Smaller company — thin liquidity and deep drawdowns are normal here

P/E (Trailing)

75.3x

Expensive

Expensive — verify against sector peers

P/B Ratio

14.73x

Rich

Steep premium to book — needs high, durable returns to justify

EPS (TTM)

₹18.19

Profitable

Profitable on a per-share basis

ROE

18.1%

Strong

Strong capital efficiency

ROCE

19.1%

Strong

Earns comfortably above its likely cost of capital

Debt/Equity

0.44x

Low

Conservative leverage

Revenue Growth (YoY)

22.8%

Healthy

Healthy top-line growth

Profit Growth (YoY)

37.3%

Healthy

Profits growing at a healthy clip

Dividend Yield

0.15%

Modest

Small cash return — most of the return has to come from the price

Free Cash Flow

₹88 Cr

Cash generative

Generates cash even after funding its capex

More Metrics

P/E (Forward)

49.7x

Improving

Below the trailing multiple — the street expects earnings to grow into the price

Operating Margin

31.8%

Good

Healthy core-business profitability

Net Margin

21.9%

Good

Strong bottom-line conversion

Current Ratio

2.60

Comfortable

Healthy short-term liquidity

Beta (vs Nifty)

0.36

Defensive

Steadier than the market

52W Range Position

70%

Mid-range

Technical Snapshot

SMA 20 / SMA 50

1466.6 / 1471.8

Bearish alignment (short < long)

Price vs SMA 200

Above

Long-term uptrend

RSI (14)

24.9

Oversold zone

Financial Trend (4-Year)

Metric	FY23	FY24	FY25	FY26	3Y CAGR
Revenue	₹459 Cr	₹548 Cr	₹681 Cr	₹814 Cr	+21.0%
EBITDA	₹190 Cr	₹225 Cr	₹277 Cr	₹341 Cr	+21.6%
EBITDA Margin	41.4%	41.1%	40.7%	41.9%	—
PAT (Net Profit)	₹85 Cr	₹119 Cr	₹144 Cr	₹173 Cr	+26.9%
EPS	₹8.26	₹11.59	₹13.97	₹16.79	+26.7%
ROE	15.5%	18.1%	18.0%	18.1%	—
ROCE	16.9%	19.9%	19.6%	19.1%	—
Total Debt	₹248 Cr	₹259 Cr	₹320 Cr	₹423 Cr	+19.5%
Free Cash Flow	₹40 Cr	₹95 Cr	₹129 Cr	₹88 Cr	+30.2%

🟢 Revenue has grown at 21.0% a year over 3 years.

🟢 EBITDA has grown at 21.6% a year over 3 years.

🟡 EBITDA Margin has held roughly flat at 41.9% over 3 years.

🟢 PAT (Net Profit) has grown at 26.9% a year over 3 years.

🟢 EPS has grown at 26.7% a year over 3 years.

🟢 ROE has risen from 15.5% to 18.1% over 3 years (+2.5 pts).

🟢 ROCE has risen from 16.9% to 19.1% over 3 years (+2.2 pts).

🔴 Total Debt has grown at 19.5% a year over 3 years.

🟢 Free Cash Flow has grown at 30.2% a year over 3 years.

Balance Sheet & Cash Flow — FY2026

Total Assets

₹1,507 Cr

Total Liabilities

₹550 Cr

Cash & Equivalents

₹40 Cr

Operating Cash Flow

₹271 Cr

Capex

-₹183 Cr

Shareholding (proxy)

Institutional Holding

39.5%

Insider Holding

53.5%

Corporate Actions

Dividend Rate

₹2

Ex-Dividend Date

16 Sept 2026

Analyst Consensus

Recommendations

8 Buy · 1 Hold · 0 Sell

Target Price (Mean)

₹1,554.8

+13.4% vs CMP

Target Range

₹1,400 – ₹1,700

Peer Comparison

Company	P/E	ROE
SUN PHARMACEUTICAL IND L	34.9x	14.5%
CIPLA LTD	31.8x	9.8%
DR. REDDY S LABORATORIES	31.0x	8.8%
APOLLO HOSPITALS ENTER. L	54.3x	22.0%

Recent News

4 mixed2 general

₹1,324 - That's What Analysts Think Vijaya Diagnostic Centre Limited (NSE:VIJAYA) Is Worth After These Results

Simply Wall Street, 12 MayAnalyst view

🟡Mixed / dependsBroker commentary — an opinion about the price rather than new information about the business.

Vijaya Diagnostic Centre Share Price Falling Today: Stock Drops 5.11% to Rs 1,340.30 on 17 July 2026

Univest, 17 JulPrice move

🟡Mixed / dependsA price move rather than a change in the business. If the figures on this page have not moved, the fall is either an opportunity or news they have yet to catch up with.

Vijaya Diagnostic Centre Reports Q1 Net Profit of 531m Rupees on Revenue of 2.31b

Sahi, 07 AugResults

🟡Mixed / dependsA results event. The figures on this page update once the new statements reach the data feed, which usually lags the announcement.

Vijaya Diagnostic gains over 3% as Emkay reiterates buy, sees strong growth across key markets

Moneycontrol.com, 25 Jun

Vijaya Diagnostic Share Price Falls After Intraday High as Profit Booking Hits Stock

Kalkine India, 03 JunPrice move

🟡Mixed / dependsA price move rather than a change in the business. If the figures on this page have not moved, the fall is either an opportunity or news they have yet to catch up with.

Is India’s diagnostics sector poised for a long-term growth upswing? Axis Securities sees opportunity in three stocks

Livemint, 12 Oct

Watch Items

Cross-check against the company's latest quarterly filing / investor presentation before acting.
RSI is in oversold territory — could mean either a bargain or a stock still falling for good reason. Check the 'why' before assuming reversal.

DalalBaazaar Thesis

StrongBusiness Quality · Financial Health · Growth · Profitability

MiddlingRisk

WeakValuation

Points for each in the Score ↑

Good business, demanding price

The quality is real and the price already reflects it. Buying here is a bet that the business keeps compounding for long enough to grow into the multiple — which good businesses often do, but it removes the margin for error that a lower price would have given you. 2 high-severity red flags sit above this conclusion and should be read first.

All 5 tripwires holding · see Key things to watch ↑